Cyclacel
Pharmaceuticals, Inc. CYCC CYCCP (Cyclacel or the Company),
a biopharmaceutical company developing oral therapies that target the various
phases of cell cycle control for the treatment of cancer and other serious
disorders announced today that updated Phase 3 clinical trial results for the
treatment of elderly patients with newly diagnosed acute myeloid leukemia
(AML) treated with sapacitabine and decitabine administered in alternating
cycles will be presented at a poster presentation during the 54^th Annual
Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday,
December 9, 2012.
The poster's abstract details are as follows:
Abstract: 2630
Pooled Analysis of Elderly Patients with Newly Diagnosed AML
Title: Treated with Sapacitabine and Decitabine Administered in
Alternating Cycles
Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM Eastern Time
Hall B1-B2, Level 1, Building B (Georgia World Congress Center)
Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation:
Poster II
Poster board: The abstract is available online at:
https://ash.confex.com/ash/2012/webprogram/start.html.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in